

EFFECT OF COBALT AND CYANO-COBALAMIN ON BIOSYNTHESIS OF A10255, A THIOPEPTIDE ANTIBIOTIC COMPLEX

MONTGOMERY E. FAVRET and LAVERNE D. BOECK

The Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, U.S.A.


(Received for publication July 15, 1992)

A10255, a thiopeptide antibiotic complex shown to promote growth and alleviate acidosis in ruminants, is produced by *Streptomyces gardneri*¹⁾. This complex, containing a cyclic peptide core with an amino acid side chain²⁾, is structurally similar to the known family of antibiotics whose members include berninamycin, nosiheptide, thiostrepton, sulfomycin I and thioxamycin^{3~5)}. The major factors of the complex are A10255G and A10255B (Fig. 1). These factors are identical except for the extent of methylation at R. Factor G contains a

dehydrobutyryne residue (methyl group at R) while factor B contains a dehydronorvaline residue (ethyl group at R). A third factor, A10255E, contains a dehydronorleucine residue with an isopropyl group at R (M. DEBONO, personal communication). Initial fermentations in stirred reactors with a complex medium produced approximately 85% factor B and 15% factor G¹⁾. Subsequent fermentations in stirred reactors with a chemically defined medium produced 5% factor B and 95% factor G⁶⁾. This report describes studies employing shaken flask cultures to investigate the A10255 factor ratio reversal observed when a defined medium was substituted for the complex medium in stirred reactors.

Mycelial stock cultures of NRRL 18260 were maintained in the vapor phase of liquid nitrogen. Seed cultures were grown in 250 ml wide-mouth Erlenmeyer flasks containing a medium consisting of glucose 0.75%, glycerol 0.5%, Trypticase soy broth 3%, enzyme-hydrolyzed casein 0.5%, potato dextrin 1% and CaCO₃ 1% in deionized water, pH

Fig. 1. Structure of A10255.



ALA, alanine; DEALA, dehydroalanine; GLY, glycine; OXA, oxazole; PYR, pyridine; THR, threonine; THZ, thiazole.

Factor	R =	Residue
A10255G	CH ₃ -	Dehydrobutyryne
A10255B	CH ₃ CH ₂ -	Dehydronorvaline
A10255E	CH ₃ ² >CH- CH ₃	Dehydroleucine

7.0 before autoclaving. The flasks were inoculated from liquid nitrogen stocks (1%) and incubated 72 hours at 30°C on a gyratory shaker orbiting at 250 rpm in a 5.08 cm diameter circle. Fermentation flasks and incubation conditions were as described above, except that 2% inoculum was used and the incubation period was 5~7 days. The complex (GGCM) fermentation medium contained glucose 1%, glycerol 3%, hydrolyzed casein (Sheffield Products) 1%, molasses 4%, NaH_2PO_4 0.01% and CaCO_3 0.5%. The defined (GGA) fermentation medium contained glucose 0.5%, glycerol 3%, Na_2SO_4 0.2%, NH_4Cl 0.43%, FeCl_3 0.0062%, ZnCl_2 0.0019%, $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ 0.03%, KH_2PO_4 0.1% and CaCO_3 3.0%. A10255 was extracted from the cell mass with aqueous methanol and assayed by isocratic HPLC¹⁾.

Shaken flask fermentations of A10255 with the complex (GGCM) medium yielded 285 $\mu\text{g}/\text{ml}$ total A10255 consisting primarily of factor B (49%) with lesser amounts of factor G (41%) and minor amounts of factor E (10%). Fermentations in the defined (GGA) medium produced 550 $\mu\text{g}/\text{ml}$ total A10255 containing predominantly factor G (86%) with factor B (14%) as a minor component. Because nutrition appeared to be responsible for this factor ratio reversal, media studies were conducted to determine which component of the GGCM medium supported biosynthesis of factors B and E. Supplementing the GGA medium with either molasses or molasses ash significantly increased the ratio of factors B and E to factor G (BE/G). In comparison to the unsupplemented GGA fermentations, addition of molasses increased the BE/G ratio 21-fold and addition of molasses ash increased the BE/G ratio 63-fold. These results suggested that the GGA medium was deficient in a trace metal essential for the biosynthesis of factors B and E. Eleven different minerals were then tested individually for their effect on the biosynthesis of A10255. Of the mineral salts present as standard components of the GGA medium, only higher concentrations of FeCl_3 increased the BE/G ratio. At a concentration of 1.52 mM, FeCl_3 increased the BE/G ratio 13-fold over the control medium (*i.e.*, 0.38 mM FeCl_3). Substitution of 1.52 mM FeCl_2 for the FeCl_3 increased the BE/G ratio three-fold over the control medium. Of the mineral salts tested as supplements to the GGA medium, only CoCl_2 substantially increased the BE/G ratio. At a concentration of 2.0 μM , CoCl_2 increased the BE/G ratio 56-fold over the unsupplemented medium. Lower levels of cobalt also increased the BE/G

Table 1. Effect of cobalt supplementation on A10255 factor biosynthesis in GGA medium.

Cobalt addition (μM) ^a	Factor			BE/G ^b	Total A10255 (% of control) ^c
	G	B	E		
None ^c	86 ^d	14	0	0.16	100
0.01	68	37	1	0.56	103
0.5	9	62	29	10.1	74
2.0	10	62	28	9.0	74
10.0	7	57	36	13.2	50

^a Chloride salt, filter-sterilized.

^b Ratio of factors B and E to factor G.

^c Control, unmodified GGA medium.

^d Percent of total.

Table 2. Effect of cyanocobalamin on A10255 factor biosynthesis in GGA medium.

Cyanocobalamin addition (μM) ^a	Factor			BE/G ^b	Total A10255 (% of control) ^c
	G	B	E		
None ^c	86 ^d	14	0	0.16	100
0.01	65	34	1	0.54	103
0.5	9	65	26	10.1	112
2.0	7	61	32	13.3	95
10.0	5	63	32	19.0	88

^a Filter-sterilized.

^b Ratio of factors B and E to factor G.

^c Control, unmodified GGA medium.

^d Percent of total.

ratio (Table 1). Cobalt is an essential component of cobalamin (vitamin B₁₂), a coenzyme involved in methylation and rearrangement reactions⁷⁾. Therefore, the effect of cobalamin supplementation on methylated factor biosynthesis was tested. As with cobalt, supplementing the GGA medium with low concentrations of cyanocobalamin significantly increased the BE/G ratio (Table 2). Further, supplementation of the GGA medium with equivalent molar concentrations of either cobalt or cyanocobalamin produced similar factor ratios. A similar effect has been reported for the methylated antibiotics mitomycin⁸⁾, fortimicin A⁹⁾ and coumermycin A₁¹⁰⁾, whose levels were increased by addition of either cobalt or cobalamin to the fermentation.

The stimulation of factors B and E biosynthesis by iron was apparently due to cobalt present as an impurity. Quantitative analyses by atomic absorption spectroscopy indicated that ferric chloride contained 0.019 μg cobalt/mg while ferrous chloride contained 0.004 μg cobalt/mg. These levels of cobalt were adequate for stimulation of factors B and E

biosynthesis. The dissimilar degree of stimulation demonstrated by the two forms of iron was apparently due to differences in the amount of cobalt each contained as an impurity. Enhancement of biosynthesis due to an impurity was reported by CLARIDGE *et al.*, who attributed stimulation of coumermycin A₁ synthesis by nickel to small amounts of cobalt present in the nickel¹⁰.

Cobalamin is a coenzyme for the methyltransferase mediating the terminal step in the biosynthesis of methionine, a common donor of methyl groups via *S*-adenosylmethionine¹¹). The effect demonstrated by addition of cobalt or cobalamin to the GGA medium was postulated to be due to increased synthesis of methionine, which then increased the BE/G ratio by functioning as a methyl donor for factor G. Addition of methionine (10mM) to the GGA medium resulted in a small increase in the percentage of factors B and E (BE/G ratio=0.30), much less than that resulting from cobalt or cobalamin supplementation. Methionine addition to the GGA medium supplemented with cobalt did not alter the factor ratio, although total synthesis was decreased. However, incorporation studies with L-[methyl-¹³C]methionine have demonstrated that methionine is a methyl donor for the additional methyl groups of factors B and E¹²).

Acknowledgments

We are sincerely grateful for the technical assistance of STEVEN LAWRENCE in performing the analytical HPLC assays used to quantitate A10255.

References

- 1) BOECK, L. D.; D. M. BERRY, F. P. MERTZ & R. W. WETZEL: A10255, a complex of novel growth-promoting thiopeptide antibiotics produced by a strain of *Streptomyces gardneri*. Taxonomy and fermentation studies. *J. Antibiotics* 45: 1222~1230, 1992
- 2) DEBONO, M.; R. M. MOLLOY, J. L. OCCOLOWITZ, J. W. PASCHAL, A. H. HUNT, K. H. MICHEL & J. W. MARTIN: The structures of A10255B, -G and -J: New thiopeptide antibiotics produced by *Streptomyces gardneri*. *J. Org. Chem.* 57: 5200~5208, 1992
- 3) ABE, H.; K. KUSHIDA, Y. SHIOBARA & M. KODAMA: The structures of sulfomycin I and berninamycin A. *Tetrahedron Lett.* 29: 1401~1404, 1988
- 4) FLOSS, H. G. & J. M. BEALE: Biosynthetic studies on antibiotics. *Angew. Chem. Int. Engl.* 28: 146~177, 1989
- 5) MATSUMOTO, M.; Y. KAWAMURA, Y. YASUDA, T. TANIMOTO, K. MATSUMOTO, T. YOSHIDA & J. SHOJI: Isolation and characterization of thioxamycin. *J. Antibiotics* 42: 1465~1469, 1989
- 6) BOECK, L. D.; M. E. FAVRET & R. W. WETZEL: Biosynthesis of thiopeptide antibiotic A10255 in stirred reactors using a chemically defined medium supplemented with continuous nutrient feeds. *J. Antibiotics* 45: 1278~1285, 1992
- 7) ABELES, R. H. & D. DOLPHIN: The vitamin B₁₂ coenzyme. *Accts. Chem. Res.* 9: 114~120, 1970
- 8) NISHIKOHRI, K. & S. FUKUI: Biosynthesis of mitomycin in *Streptomyces caespitosus*. Relationship of intracellular vitamin B₁₂ level to mitomycin synthesis and enzymatic methylation of a demethylated derivative of mitomycin. *Eur. J. Appl. Microbiol.* 2: 129~145, 1975
- 9) YAMAMOTO, M.; R. OKACHI, I. KAWAMOTO & T. NARA: Fortimicin A production by *Micromonospora olivoasterospora* in a chemically defined medium. *J. Antibiotics* 30: 1064~1072, 1977
- 10) CLARIDGE, C. A.; R. P. ELANDER & K. E. PRICE: The coumermycins: properties, biosynthesis and fermentation. *In* *Biotechnology of Industrial Antibiotics*. Ed., E. J. VANDAMME, pp. 413~425, Marcel Dekker, Inc., 1984
- 11) SALEM, A. R. & M. A. FOSTER: The microbial biosynthesis of methionine. *Biochem. J.* 127: 845~853, 1972
- 12) FAVRET, M. E.; J. W. PASCHAL, T. K. ELZEY & L. D. BOECK: Biosynthesis of thiopeptide antibiotic A10255: Incorporation of isotopically-labeled precursors. *J. Antibiotics* 45: 1499~1511, 1992